HIF1A and breast carcinoma: Echinomycin, a small-molecule inhibitor of HIF-1/DNA binding, did not show significant antitumor activity in phase II studies in patients with ovarian cancer, breast cancer, renal cell carcinoma, or CRC [203,204,205,206].